FLT3 and acute myeloid leukemia: In an evaluation of the impact of sequential FLT3 TKI therapy in patients with FLT3-mutated AML, Yilmaz and colleagues reported that the rate of CRc declined from 77% for FLT3 TKI therapy in the frontline setting to 31% for TKI therapy administered in the R/R AML setting; the CRc rate further declined to 25% after the third TKI [33].